Fresh start private management, inc.

Filed 05/01/13 for the Period Ending 04/30/13 999 N. TUSTIN AVENUESUITE 16SANTA ANA, CA 92705 8093 - Specialty Outpatient Facilities, Not Elsewhere Classified Copyright 2013, EDGAR Online, Inc. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use.
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
April 30, 2013
Date of Report (Date of earliest event reported) FRESH START PRIVATE MANAGEMENT INC.
(Exact name of registrant as specified in its charter) 333-153381
720 N. Tustin Avenue
Suite 206
Santa Ana, California
(Address of principal executive offices) (714) 541-6100
Registrant’s telephone number, including area code (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
License Agreement
Fresh Start Private Management Inc., a Nevada corporation (the "Company") is involved in establishing alcohol rehabilitation and treatment
centers and has created an alcohol rehabilitation program consisting of a Naltrexone implant that is placed under the skin in the lower abdomen
coupled with life counseling sessions from specialized counselors. The Naltrexone implant is manufactured by Trinity Rx Solutions LLC
("Trinity Rx"). The Company has an exclusive license with Trinity Rx pursuant to which Trinity Rx provides the Company with the Naltrexone
Effective on April 5, 2013, the Board of Directors of the Company authorized the execution of that certain ten year sub-license agreement
amongst the Company, Kryptonite Investments LLC ("Kryptonite Investments") and Trinity dated April 8, 2013 (the "License Agreement"),
pursuant to which Kryptonite Investments shall acquire an exclusive license (the "License") solely for the State of Arizona for the purpose of
receiving, implanting, using, selling and otherwise importing for commercializing the Naltrexone implant.
In accordance with the terms and provisions of the License Agreement: (i) the License shall be granted by the Company to Kryptonite
Investments upon payment of $425,000 to the Company as evidenced by that certain convertible debenture agreement (the "Debenture"); and
(ii) the Company shall grant to Kryptonite Investments the exclusive rights to the License to use, sell and offer for sale in the State of Arizona
the Naltrexone implant and includes the Company's copyrighted, trademarked or patented materials inclusive of name, logo and other
Company materials, such as advertising, marketing, publicity, public relations and publications.
In further accordance with the terms and provisions of the License Agreement, Kryptonite Investments shall pay the following amounts to the
Company a license fee of $300,000 (the "License Fee"), which shall be payable as either: (i) an upfront License Fee less 10% discount for total
of $270,000 if paid within 30 days of date that all principal and interest is repaid by the Company for the Debenture; or (ii) additional royalty
fee of 10% in addition to the running royalty fee (defined below) to be allocated towards the License Fee of $300,000, which additional royalty
is to begin within 30 days of principal and interest being paid in full for the Debenture by the Company and the additional royalty shall cease
once the $300,000 is received by the Company from Kryptonite Investments for the license fee.
The License Agreement provides that there shall be a running royalty fee of 10% (the "Running Royalty Fee") on each Naltrexone implant with
the applicable royalty rate (the "Royalty Fee"), which Running Royalty Fee shall be paid to the Company after the Company has paid the
Debenture. In accordance with the terms and provisions of the License Agreement, Kryptonite Investments shall pay to the Company: (i) a
Royalty Fee of 10% of the gross payment received, which shall be paid monthly beginning the first of the month following the first implant
procedure conducted by Kryptonite Investments; and (ii) the Running Royalty Fee.
Lastly, in accordance with the License Agreement, the Company shall provide to Kryptonite Investments: (i) support and training for efficient
operations; (ii) all documentation and procedural support for patient requirements, surgical procedures, billing, claims and other operational
documentation; (iii) known compliance requirements of insurers and Medicare; (iv) insurance claim pre-authorization, billing procedures and
support; (v) patient forms and testing requirements; (vi) implant procedures, training and support; (viii) requirements for hiring, training and
supporting life coaching counselors; (ix) all medical procedure documentation from a licensed physician and list of medical supplies needed to
perform the implant procedure; (x) access to medical training by doctors as to how to perform the insertion of the Naltrexone implant; and (xi)
marketing and educational videos, advertising materials, participation in clinical studies and results and referrals of any inquiries within the
State of Arizona.

Securities Purchase Agreement
In conjunction with the License Agreement, the Company entered into that certain securities purchase agreement dated April 5, 2013 (the
"Securities Purchase Agreement") with the principals of Kryptonite Investments (collectively, the "Principals"). In accordance with the terms
and provisions of the Securities Purchase Agreement: (i) the Company shall sell and issue to the Principals up to 140 units (the "Unit") at a per
Unit price of $25,000 for aggregate gross proceeds of up to $6,000,000. Each Unit shall consist of: (i) the one year Debenture in the face
amount of $25,000, which is convertible into 50,000 shares of the Company's common stock at a conversion price of $0.50 per share; (ii) three
(3) shares of the Company's common stock for each $1.00 of principal amount and 300% warrants coverage exercisable at $1.00 per share of
common stock, and maturing not later than five (5) years following the closing (the "Series A Common Stock Purchase Warrant");
Therefore, in accordance with the terms and provisions of the License Agreement and the Securities Purchase Agreement, the Company has
issued an aggregate of 17 Units to the Principals for aggregate proceeds of $425,000.
Effective on April 8, 2013, the Company granted an aggregate of 17 shares of its restricted common stock to the Principals, which constituted
four U.S. residents. In accordance with the terms and provisions of the Securities Purchase Agreement, the Principals acquired an aggregate of
17 shares of the Company's restricted common stock as part of the Unit.
The shares were granted to four United States residents in reliance on Section 4(2) of the United States Securities Act of 1933, as amended (the
“Securities Act”). The shares of common stock have not been registered under the Securities Act or under any state securities laws and may not
be offered or sold without registration with the United States Securities and Exchange Commission or an applicable exemption from the
registration requirements. The Principals acknowledged that the securities to be issued have not been registered under the Securities Act, that
they understood the economic risk of an investment in the securities, and that they had the opportunity to ask questions of and receive answers
from the Corporation’s management concerning any and all matters related to acquisition of the securities.
Item 9.01 Financial Statements and Exhibits
(a) Financial Statements of Business Acquired.
Not applicable.
(b) Pro forma Financial Information .
Not applicable.
(c) Shell Company Transaction.
Not applicable.
(d) Exhibits.
Not applicable.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FRESH START PRIVATE MANAGEMENT INC.
DATE: April 30, 2013
Name: Dr. Jorge Andrade
Title: Chief Executive Officer/Secretary


(Actos cuja publicação é uma condição da sua aplicabilidade) REGULAMENTO (CE) N.o 1606/2002 DO PARLAMENTO EUROPEU E DO CONSELHO de 19 de Julho de 2002 relativo à aplicação das normas internacionais de contabilidade O PARLAMENTO EUROPEU E O CONSELHO DA UNIÃO EUROPEIA,de 1986, relativa às contas anuais e às contas consoli-dadas dos bancos e outras instituiço˜es financeiras (

Pharmacokinetic parameters of Gtfx after oral administration in dogs( n = 4) Concentration - time curves of Gtfx after oral administration in dogs serum( n = 4) Perry CM , Balfour JAB , Lamb HM. Catifloxacin[J ] . Drugs ,1999 ,58Stahlberg HJ , Cohler K , Cuillane M , et al . Effeets of gatifloxacin me2sylate ( GTFX) on the pharmacokinetics of theophyline in heathly youngvolun

© 2010-2017 Pdf Pills Composition